A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Vilanterol/fluticasone furoate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms CAPTAIN
- Sponsors GlaxoSmithKline
- 06 Jul 2017 Planned End Date changed from 27 Feb 2018 to 10 Sep 2018.
- 06 Jul 2017 Planned primary completion date changed from 27 Feb 2018 to 10 Sep 2018.
- 24 Apr 2017 Planned End Date changed from 1 Feb 2018 to 27 Feb 2018.